Q-omics provides the consensus-scored STS profile across patient tissues and cancer cell-line models. STS expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, STS is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, STS RNA expression shows 18,942 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where STS shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for STS — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes STS survival associations across molecular data types. STS RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible STS RNA expression–survival associations across cancer types. High STS expression shows unfavorable associations in UVM, ESCA, LUSC and KICH, but favorable associations in KIRC and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for STS RNA expression.
This table summarizes STS tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in KIRP for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for STS. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. STS shows lower tumor expression in LUSC, KICH and BRCA and higher tumor expression in KIRP, KIRC and PAAD. The KIRP box plot shows higher STS RNA expression in tumor versus normal tissue (log2 FC = +1.250, t-test p < 0.001).
This table shows molecular features associated with STS in patient tissues and cancer cell lines. In patient samples, STS shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, STS RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
